OSAKA SODA (4046) FY2027 Q1 Earnings Report

Quick View

Executive Summary

FY2027 Q1 delivered higher revenue and earnings, significantly exceeding the same period of the previous year on both sales and profit. Revenue was ¥287.5B (+18.4% YoY), Operating Income was ¥62.4B (+58.3%), Ordinary Income was ¥70.6B (+58.8%), and Net Income was ¥49.5B (+62.4%). The Operating Income margin expanded to 21.7%, up 550bp from 16.2% in the same period of the previous year. Profit growth exceeding the rate of revenue growth was driven by an improved earnings mix centered on Functional Chemicals and Basic Chemicals, as well as fixed-cost absorption.

Factors Affecting Business Performance

【Revenue】Revenue was ¥287.5B, up +18.4% YoY. By segment, Basic Chemicals generated ¥112.7B (39.2% of total, +17.4%), Functional Chemicals ¥85.1B (29.6%, +17.3%), Healthcare ¥43.8B (15.2%, +43.3%), and the Trading Business and Others ¥52.1B (18.1%, -5.3%). Healthcare recorded the highest revenue growth rate and led overall growth. By region, domestic revenue was ¥168.7B, accounting for 58.7% of total revenue, while overseas expansion was notable, with revenue to China up +39.0%, revenue to Asia up +36.6%, and revenue to Europe up +26.8%.

【Profit and Loss】Operating Income was ¥62.4B (+58.3% YoY), and the Operating Income margin improved by 550bp to 21.7%. Functional Chemicals achieved substantial profit growth of +134.0%, with its profit margin rising to 29.5% (28.6% in the previous year), making it the largest contributor to earnings growth. Basic Chemicals also improved, with profit up +33.2% and the profit margin rising to 14.6% (12.8% previously). Meanwhile, Healthcare profit increased by only +28.4% against revenue growth of 43.3%, and its profit margin declined by approximately 570bp YoY to 49.1%. Non-operating income was ¥8.9B, primarily consisting of ¥5.7B in dividend income. Net extraordinary income and losses were minimal at ¥0.33B. Accordingly, the increases in Ordinary Income and Net Income were driven by the core business and recurring non-operating income. In conclusion, the Company achieved higher revenue and earnings.

Segment Analysis

Healthcare generated revenue of ¥43.8B (+43.3%) and Operating Income of ¥21.5B (+28.4%), accounting for 32.8% of total segment profit and representing the largest profit-contributing business; however, its profit margin declined by 570bp YoY to 49.1%. Functional Chemicals recorded the highest profit growth, with revenue of ¥85.1B (+17.3%) and profit of ¥24.4B (+134.0%), while its profit margin also improved to 29.5%. Basic Chemicals generated revenue of ¥112.7B (+17.4%) and profit of ¥16.4B (+33.2%), with its profit margin rising to 14.6%. The Trading Business and Others showed weak momentum, with revenue of ¥52.1B (-5.3%) and profit of ¥3.2B (-0.3%); its profit margin was 6.2%, indicating a significant profitability gap relative to the other businesses. The adjustment for company-wide expenses was △¥3.19B.

Key Financial Indicators

【Profitability】The Operating Income margin of 21.7%, Net Income margin of 17.2%, and Gross Profit margin of 36.6% all significantly exceeded the levels in the same period of the previous year. High-value-added areas, particularly Functional Chemicals and Basic Chemicals, supported profitability.【Cash Quality】Cash and deposits were ¥154.6B, while accounts receivable and notes receivable were ¥296.5B and inventories were ¥126.3B, indicating a large working capital base. Progress in converting earnings growth into cash will be a key focus going forward.【Investment Efficiency】ROE was 3.8%. Despite the high profit margin relative to total assets of ¥1,710.0B, the low total asset turnover and an asset composition including ¥396.7B in investment securities are constraining capital efficiency. EPS was ¥40.49 (¥24.22 in the previous year, +67.2%).【Financial Soundness】The Equity Ratio was 76.3% (76.2% in the previous year). Liquidity was ample, with current assets of ¥967.4B versus current liabilities of ¥308.5B. Interest-bearing debt consisted solely of ¥71.7B in short-term borrowings, indicating a conservative and robust financial foundation.

Cash Flow Analysis

As the Company has not disclosed a statement of cash flows in this earnings report, funding trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥154.6B, down from ¥218.6B in the same period of the previous year, while investment securities stood at ¥396.7B and current securities at ¥269.4B, suggesting that part of the funds has been allocated to financial assets. Accounts receivable and notes receivable were ¥296.5B, and inventories were ¥126.3B; both increased from the same period of the previous year, indicating an accumulation of working capital in line with revenue expansion. Retained earnings increased to ¥918.3B, showing that earnings growth is being accumulated as internal reserves. Net assets were ¥1,304.5B, maintaining an Equity Ratio of 76.3%, and the funding base remains stable. The key to converting earnings growth into actual cash generation will be the collection of receivables and the trend in inventory levels going forward.

Quality of Earnings

The main drivers of the increase in Net Income to ¥49.5B were the expansion of Operating Income from the core business and recurring non-operating income, while the impact of one-time extraordinary income and losses was limited. Extraordinary income of ¥1.2B (gain on sale of fixed assets) and extraordinary loss of ¥0.8B (loss on disposal of fixed assets) resulted in net extraordinary income of only ¥0.33B. Of Pre-Tax Income of ¥70.9B, the majority consisted of Operating Income of ¥62.4B and non-operating income of ¥8.9B. Non-operating income was primarily dividend income of ¥5.7B, representing stable income from investments held. Foreign exchange gains of ¥1.2B also contributed partially, although these may become a source of volatility if exchange rate trends reverse. Comprehensive Income was ¥67.6B, exceeding Net Income of ¥49.5B. The difference was attributable to a ¥17.8B increase in valuation difference on securities, indicating that changes in the market value of equity holdings boosted Comprehensive Income separately from the earnings power of the core business. Overall, recurring business income is the primary source of profit, and earnings quality can be assessed as relatively high.

Earnings Forecast and Guidance

The Full-Year plan calls for Revenue of ¥1,080.0B (+8.0% YoY), Operating Income of ¥205.0B (+16.2%), and Ordinary Income of ¥221.0B (+12.7%). Both the earnings forecast and dividend forecast have been revised. Q1 progress rates were 26.6% for Revenue, 30.4% for Operating Income, 31.9% for Ordinary Income, and 33.4% for Net Income, with profit progress exceeding revenue progress. In particular, the Operating Income progress rate was 5.4pt above the simple progress benchmark of 25%, and the Q1 Operating Income margin of 21.7% was also above the Full-Year plan Operating Income margin of 19.0%. At present, profit accumulation toward the plan is progressing favorably.

Shareholder Returns

The Full-Year dividend forecast is ¥30.0 per share, resulting in a Payout Ratio of 24.6% against forecast EPS of ¥121.74. This represents an increase compared with the dividend of ¥12 in the same period of the previous year, and the dividend forecast has been revised. The Payout Ratio of 24.6% is substantially below the general sustainability benchmark of approximately 60%. Financial capacity, including an Equity Ratio of 76.3% and cash and deposits of ¥154.6B, also supports dividend sustainability. Q1 Net Income reached 33.4% of the Full-Year forecast, indicating steady accumulation of funds available for dividends.

Risk Factors

1. Prolonged working capital cycle: Accounts receivable and notes receivable of ¥296.5B and inventories of ¥126.3B increased from the same period of the previous year. The accumulation of receivables and inventories accompanying revenue expansion presents a risk of delaying the conversion of earnings growth into cash. In particular, the utilization of product inventories of ¥126.3B will be a key focus.

2. Decline in Healthcare profit margin: Healthcare, the largest profit-contributing business, saw its segment profit margin decline by approximately 570bp YoY to 49.1%. Changes in product mix, promotional expenses, and development expenses could have a significant impact on consolidated profitability.

3. Dependence on short-term borrowings: Interest-bearing debt of ¥71.7B consists entirely of short-term borrowings, creating sensitivity to refinancing terms and short-term interest rate movements. However, cash and deposits are equivalent to 2.16 times short-term borrowings, ensuring sufficient near-term liquidity.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin significantly exceed the industry median, placing the Company’s profitability in the upper tier of the industry.

Growth and Capital Efficiency

The Revenue growth rate also significantly exceeds the industry median, placing the Company’s revenue growth pace at a high level within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Report

1. The Operating Income margin improved by 550bp to 21.7%, with Functional Chemicals (profit +134.0%) and Basic Chemicals (profit +33.2%) driving earnings growth. A key feature of this earnings report is that Healthcare recorded the highest revenue growth rate while its profit margin declined, resulting in divergent profitability trends among the businesses.

2. Q1 progress rates against the Full-Year plan were 30.4% for Operating Income and 33.4% for Net Income, exceeding the simple progress benchmark of 25%. Progress toward achieving the plan is therefore favorable from a profit perspective.

3. The financial foundation is robust, with an Equity Ratio of 76.3% and an implied current ratio of 313.6% (current assets of ¥967.4B / current liabilities of ¥308.5B). However, increases in accounts receivable and inventories warrant attention from a working capital management perspective.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,118–¥1,185 at ±1% for the cost of equity, and ¥1,149–¥1,154 at ±0.1 for ω.

Notes:

• Net assets as of the quarter-end have been used (there is a timing difference from the Full-Year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model used: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Osaka Soda delivered a very strong FY2027 Q1, with broad-based sales growth and substantial operating-margin expansion. Revenue increased 18.4% year on year to ¥28.75bn. Operating income rose 58.3% to ¥6.24bn, materially outpacing revenue growth. Ordinary income increased 58.8% to ¥7.06bn. Net income attributable to owners grew 62.3% to ¥4.95bn. Gross profit increased 35.1% to ¥10.52bn, reflecting a favorable cost-of-sales increase of only 10.8% versus revenue growth of 18.4%. The gross margin expanded to 36.6% from 32.0%, a 460bp improvement. The operating margin expanded to 21.7% from 16.2%, a 550bp improvement. The net margin rose to 17.2% from 12.5%, a 470bp improvement. Functional Chemicals was the largest contributor to segment profit, generating ¥2.44bn, while Healthcare retained the highest segment margin at 49.1%. Basic Chemicals also delivered a meaningful earnings recovery, with segment profit up 33.2%. Operating leverage was favorable because SG&A increased 11.4%, below revenue growth. Non-operating income of ¥0.89bn was led by ¥0.57bn of dividend income and therefore supported, rather than replaced, strong operating earnings. Small net extraordinary gains of ¥0.03bn had an immaterial impact on profit before tax. The annualized ROE was 15.2%, supported primarily by the 17.2% net margin rather than aggressive leverage. The balance sheet remains strongly capitalized, with a 313.6% current ratio, 76.3% equity ratio, and only 5.2% debt-to-capital. Management's full-year forecast implies that Q1 operating-income progress of 30.4% is ahead of the standard 25% seasonal benchmark, though not by more than 10 percentage points. The principal operating items to monitor are the elevated receivable and inventory day metrics, as working-capital efficiency will determine whether the strong accounting profit converts into cash.

Profitability Analysis

Annualized DuPont ROE was 15.2%, comprising a 17.2% net profit margin, 0.672x annualized asset turnover, and 1.31x financial leverage. The dominant driver of returns is profitability: the net margin rose 470bp year on year, while leverage remains conservative. The EBIT margin was 21.7%, and the tax burden was 0.698, consistent with the reported 30.2% effective tax rate. Interest burden was favorable at 1.137 because non-operating income exceeded interest costs, while interest coverage was an exceptionally strong 152.07x. Gross margin expanded 460bp as sales rose faster than cost of sales, and operating margin expanded a further 90bp relative to gross-margin expansion because SG&A growth of 11.4% remained below revenue growth. Functional Chemicals was the core business by operating-income contribution, representing 37.2% of aggregate segment profit before corporate costs; its revenue increased 17.5% to ¥8.28bn and segment profit surged 134.0% to ¥2.44bn, lifting its segment margin to 29.5% from 14.8%. Healthcare revenue rose 43.3% to ¥4.38bn and segment profit increased 28.4% to ¥2.15bn; its 49.1% margin was the highest among segments, despite declining from 54.8% a year earlier. Basic Chemicals revenue increased 17.4% to ¥11.27bn and segment profit rose 33.2% to ¥1.64bn, with margin improving to 14.6% from 12.8%. Trading and other revenue grew 5.2% to ¥4.82bn, while segment profit was essentially flat at ¥0.32bn and margin declined to 6.7% from 7.1%. Corporate costs declined from ¥0.34bn to ¥0.32bn. The margin improvement appears predominantly operational, given broad segment revenue growth and the limited contribution from small extraordinary gains.

Growth Assessment

Growth was broad based geographically and by operating segment. Domestic revenue increased 10.8% to ¥16.87bn, China revenue increased 39.0% to ¥4.10bn, Asia revenue increased 36.6% to ¥4.04bn, and Europe revenue increased 26.8% to ¥2.52bn. The strongest segment sales growth was Healthcare, followed by Basic Chemicals and Functional Chemicals. Functional Chemicals generated the strongest incremental profit growth, suggesting improved product mix, pricing, utilization, or operating efficiency within that business. Healthcare remains a high-margin growth engine, but its lower margin indicates that the mix and cost base should be monitored as sales scale. Full-year company guidance calls for revenue of ¥108.00bn, operating income of ¥20.50bn, ordinary income of ¥22.10bn, and net income of ¥14.80bn. Q1 progress was 26.6% for revenue, 30.4% for operating income, 31.9% for ordinary income, and 33.4% for net income, compared with a standard first-quarter progress rate of 25%. Operating-income progress is 5.4 percentage points ahead of the standard pace, while net-income progress is 8.4 percentage points ahead. These deviations do not exceed the 10-percentage-point threshold, but they leave the company positioned ahead of its initial annual earnings cadence. The forecast incorporates 8.0% revenue growth and 16.2% operating-income growth for the full year, implying margin normalization from the unusually strong Q1 level. Forecast and dividend revisions are indicated, making subsequent management guidance and the persistence of Functional Chemicals profitability key determinants of the outlook.

Financial Health

Financial health is strong. Current assets of ¥96.74bn exceeded current liabilities of ¥30.85bn, producing working capital of ¥65.89bn and a current ratio of 313.6%. The quick ratio was also robust at 272.6%, demonstrating that liquidity does not depend on inventory liquidation. Cash and deposits were ¥15.46bn, equivalent to 2.16x short-term loans of ¥7.17bn. Debt-to-equity was 0.31x and debt-to-capital was 5.2%, supporting a conservative solvency profile. All reported interest-bearing loans were short term, resulting in a 100.0% short-term debt ratio and a refinancing-risk alert. The root cause is the concentration of loan maturities in the near term rather than an excessive absolute debt balance. This maturity profile is mitigated by cash coverage, ample liquid current assets, and exceptionally high interest coverage, but it still leaves funding costs and bank-market access as items to monitor. Total liabilities represented only 23.7% of total assets, while total equity was ¥130.45bn and the equity ratio was 76.3%. Cash and deposits declined 29.3% year on year, from ¥21.86bn to ¥15.46bn; despite the strong liquidity ratios, this reduces the immediate cash buffer and warrants attention alongside working-capital demands. Investment securities increased to ¥39.67bn and account for 23.2% of total assets, creating meaningful exposure of equity and comprehensive income to market-value movements. Asset retirement obligations were ¥0.66bn, equal to approximately 1.6% of liabilities, a manageable level for a chemical manufacturer. Lease obligations of ¥0.53bn are included in noncurrent liabilities.

Notable B/S Changes

Cash and deposits: -¥6.40bn (-29.3%) year on year to ¥15.46bn - lowers the immediate cash buffer, although cash still covers short-term loans by 2.16x and liquidity ratios remain strong.

Cash Flow Quality

Quarterly cash-flow figures are not provided, so operating cash flow, free cash flow, cash conversion, and cash-flow coverage of distributions cannot be quantified. Earnings quality at the income-statement level was favorable: operating income of ¥6.24bn was the primary contributor to profit, while the net extraordinary gain was only ¥0.03bn, or less than 1% of net income. Non-operating income totaled ¥0.89bn, equal to 3.1% of revenue, below the 5% threshold that would make non-operating earnings a dominant issue; dividend income of ¥0.57bn was its largest component. The receivables alert is material: annualized DSO was 94 days, above the 60-day warning level. Its root cause is a receivables balance of ¥29.65bn relative to annualized Q1 revenue, and it increases the risk that reported sales and profit are not promptly converted to cash. This collection cycle is long for the stated manufacturing benchmark and is particularly important given the decline in cash balances. The first inventory alert identifies annualized DIO of 97 days, above the 90-day warning level; this level raises the risk of cash being tied up in production and finished-goods stock, as well as potential valuation pressure if chemical demand or pricing weakens. The second inventory alert identifies annualized DIO of 63 days, which is also above the 60-day efficiency benchmark. Both inventory alerts point to a working-capital burden that requires close monitoring, even though the balance sheet has substantial liquidity. Finished goods were ¥12.63bn, while raw materials were ¥4.98bn and work in process was ¥1.79bn. Receivables increased 12.0% year on year and finished goods increased 14.8%, so cash conversion should be assessed closely in subsequent quarters.

Dividend Sustainability

The full-year dividend forecast is ¥30.00 per share, compared with forecast EPS of ¥121.74. This implies a dividend payout ratio of approximately 24.6%, which is well below the 60% sustainability benchmark. The projected dividend is therefore well covered by forecast earnings on an accounting basis. Q1 EPS was ¥40.49, equivalent to 33.3% of full-year forecast EPS, supporting the attainability of the forecast under the current earnings run rate. The indicated dividend revision should be interpreted alongside the updated forecast, the company’s cash generation, and any future treasury-share transactions. The company holds ¥15.46bn of cash and deposits against ¥7.17bn of short-term loans, while its current ratio is 313.6%, providing balance-sheet capacity for the stated dividend. Free-cash-flow coverage cannot be quantified because cash-flow and capital-expenditure figures are not provided. The ¥30.00 forecast DPS should therefore be monitored against operating cash flow and the normalization of working-capital balances, particularly receivables and inventories.

Risk Assessment

Business risks include Chemical-market cyclicality, including changes in industrial demand, product spreads, and customer inventory adjustments, could pressure the currently elevated 21.7% operating margin., Functional Chemicals has become the largest segment-profit contributor, so maintaining its 29.5% segment margin is central to group earnings resilience., Healthcare is the highest-margin business at 49.1%, but its margin declined 570bp year on year despite revenue growth, creating mix and cost-execution sensitivity., International revenue exposure is meaningful, particularly in China, Asia, and Europe; foreign-exchange movements and regional demand conditions can affect sales and profitability. Q1 included ¥0.12bn of foreign-exchange gains., Elevated inventory days expose the company to demand-forecasting, product-obsolescence, and chemical-price risks..

Financial risks include REFINANCING_RISK: the 100.0% short-term debt ratio means reported borrowing maturities are concentrated in the near term. Liquidity is ample, with cash covering short-term loans by 2.16x, but renewal terms and rates remain relevant., HIGH_RECEIVABLE_DAYS: annualized DSO of 94 days exceeds the 60-day warning threshold. Slow collection can weaken operating-cash-flow conversion and increase customer-credit exposure., HIGH_INVENTORY_DAYS: annualized DIO of 97 days exceeds the 90-day warning threshold. It signals potentially high inventory funding needs and a heightened risk of write-downs if demand or selling prices decline., HIGH_INVENTORY_DAYS: annualized DIO of 63 days exceeds the 60-day manufacturing-efficiency benchmark. This reinforces the need to monitor inventory turnover despite the company’s strong current ratio., Investment securities of ¥39.67bn represent 23.2% of total assets, and valuation gains on securities contributed ¥1.78bn to Q1 OCI; market-price volatility can affect comprehensive income and equity..

Key concerns include Whether elevated receivables and inventory balances reverse into operating cash flow., Whether Q1’s strong gross-margin expansion can be sustained as the full-year forecast implies a lower operating margin than the Q1 result., The effect of lower cash and deposits, down 29.3% year on year, when combined with short-term debt maturities., Potential volatility in dividend income and investment-security valuations, which supported non-operating income and comprehensive income..

Investment Implications

Key takeaways include Q1 earnings materially exceeded sales growth, with operating income up 58.3% and net income up 62.3%., Margin expansion was the main performance driver: gross margin increased 460bp and operating margin increased 550bp year on year., Functional Chemicals is the core profit contributor, while Healthcare provides the highest absolute segment margin., The capital structure is conservative, with a 76.3% equity ratio, 5.2% debt-to-capital, and 152.07x interest coverage., Working-capital efficiency is the primary financial-quality issue despite strong reported profitability and liquidity., Q1 progress against full-year guidance is ahead of the standard seasonal pace but does not exceed the 10-percentage-point deviation threshold..

Metrics to watch include Functional Chemicals segment margin and profit contribution, Healthcare segment margin recovery or further dilution, Annualized DSO and customer-collection trends, Annualized DIO and finished-goods inventory movement, Operating cash flow and free cash flow relative to net income, Cash and deposits relative to short-term loans, Full-year operating-margin delivery versus the ¥20.50bn operating-income forecast, Investment-security valuation effects on OCI and equity.

Regarding relative positioning, Osaka Soda’s Q1 profitability is strong by the supplied benchmarks, with a 21.7% operating margin, 17.2% net margin, and 15.2% annualized ROE. Its balance sheet is more conservatively financed than a highly leveraged chemical manufacturer, but its long receivable cycle and elevated inventory metrics are less favorable than manufacturing working-capital benchmarks.